responsabile dei programmi di ricerca
1) programma di ricerca
A phase I/Ib/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
leader del programma
2) programma di ricerca
A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
leader del programma
3) programma di ricerca
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
leader del programma
4) programma di ricerca
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
leader del programma
5) programma di ricerca
A Phase 1/1b Open-label, Multicenter Clinical Study of MK 0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors
leader del programma
6) programma di ricerca
A Phase I, Open-Label, Multicenter Study to Assess Safety, Tolerability,PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
leader del programma
7) programma di ricerca
A Phase I, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
leader del programma
8) programma di ricerca
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients
leader del programma
9) programma di ricerca
Two-part, first-in-human study on ODM-212 in subjects with selected advanced solid tumours
leader del programma
10) programma di ricerca
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid Tumors
leader del programma
11) programma di ricerca
A Phase 1, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS 986458, Alone and in Combination with Anti-lymphoma Agents in Participants with Relapsed/Refractory Non Hodgkin Lymphomas (R/R NHL)
leader del programma
12) programma di ricerca
A Phase 1 Open-Label, Multi-Center, Safety and efficacy study of PRT2527 as Monotherapy and in combination with Zanubrutinib in Participants with Relapsed/Refractory Hematologic Malignancy
leader del programma
13) programma di ricerca
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
leader del programma
14) programma di ricerca
A Phase III, Randomized, Open-Label, Multicenter Trial Of ARV-471 (PF-07850327) vs Fulvestrant In Participants With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment
leader del programma
15) programma di ricerca
A Window-of-Opportunity) trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer
leader del programma
16) programma di ricerca
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
leader del programma
17) programma di ricerca
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness
leader del programma
18) programma di ricerca
Preoperative treatment with metronidazole to evaluate the efficacy in reducing Fusobacterium nucleatum tumor colonization in patients with colorectal cancer (CRC): a proof-of-concept trial
leader del programma
19) programma di ricerca
Maintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo controlled multi-center phase III Trial (ENGOT-ov54/Swiss GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study) Clinical Study
leader del programma
20) programma di ricerca
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (ENGOT-en23/GOG3095)
leader del programma
21) programma di ricerca
A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin
leader del programma
22) programma di ricerca
A Phase II Study to Evaluate the Efficacy and Safety of MK 1026 in Participants with hematologic malignancies
leader del programma
23) programma di ricerca
A phase III, multicenter, double-blind, randomized, placebo controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy
leader del programma
24) programma di ricerca
A phase III, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FL T3 mutations eligible for intensive chemotherapy
leader del programma
25) programma di ricerca
A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS) LUSPLUS
leader del programma
26) programma di ricerca
A randomized, multicenter, open label,phase III Study of Lurbinectidin in combonation with Irinotecan versus Investigator’s choice (Topotecan or Irinotecan) in relapsed Small Cell Lung Cancer (SCLC) patients (LAGOON)
leader del programma
27) programma di ricerca
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non small cell lung cancer (NSCLC). A multicenter phase II trial.
leader del programma
28) programma di ricerca
Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer
leader del programma
29) programma di ricerca
A Phase III Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
leader del programma
30) programma di ricerca
Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)
leader del programma
31) programma di ricerca
A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
leader del programma
32) programma di ricerca
Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial
leader del programma
33) programma di ricerca
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therypy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
leader del programma
34) programma di ricerca
on physical activity and diet in patients with metastatic prostate cancer receiving novel hormonal agents: the ACTIDIET-PRO study
leader del programma
35) programma di ricerca
A single arm phase II trial of ultrahypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy
leader del programma
36) programma di ricerca
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents
leader del programma
37) programma di ricerca
Protocol SAKK 06/19 Intravesical BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single-arm phase II trial
leader del programma
38) programma di ricerca
MK-9999-02A Sub-Study: A Phase 1/2 Substudy of the MK 9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination with Other Anticancer Agents in Gastrointestinal Cancers.
leader del programma
39) programma di ricerca
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.
leader del programma
40) programma di ricerca
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305).
leader del programma